Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders

Capasso, Anna; Petrella, C.; Milano, Walter

doi:10.2174/157488409787236092

Cited by 24 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CBT is found to be effective in reducing the number of binge episodes [4]. Antidepressants are among the first drugs to be tested in the treatment of BED, where selective serotonin reuptake inhibitors are forefront [5]. Especially fluoxetine was reported to decrease weekly illness severity, frequency of binge episodes and clinicianrated depression, compared with placebo [6].…”

Section: Discussionmentioning

confidence: 99%

Methylphenidate treatment for binge-eating disorder in a 12-year-old boy

Önder¹,

Adanır

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Binge-eating disorder (BED) is defined as frequent episodes of binge eating, and the subjective feeling of loss of control over food intake, in the absence of inappropriate compensatory behaviours. Although it is one of the most common eating disorders in adults, it is less common in childhood and adolescence, and literature about its diagnosis and treatment in children and adolescents is limited. Here, we report a 12-year-old boy, with BED, who had not responded to conventional therapies, and showed recovery with methylphenidate therapy. He had lost his mother a year ago, and had depression symptoms since then, and binge-eating episodes for the last 3 months. His depression symptoms were ameliorated in a month with fluoxetine 20 mg, but his binge-eating episodes continued with the same frequency and severity, despite the drug and cognitive behavioural therapy. Twice daily short-acting methylphenidate (Ritalin 10 mg.) was added then, and with ritalin, his bingeeating episodes were dramatically decreased in frequency. Over the years, various strategies and guidelines for treatment have been proposed for BED, especially in adults, including pharmacological and psychotherapeutic strategies. Stimulants were also used for BED. Lisamfetamine has been shown to reduce the frequency of exacerbations in adults with binge-eating disorders. There are case reports about methylphenidate use for bulumia nervosa (but not for BED) in adults, but to our knowledge, to date, there is not a case reported methylphenidate use for BED in children and adolescents in the literature. In conclusion, data from these reports suggest a possible benefit of using psychostimulants in the treatment of children respond poorly to conventional therapies. Clinical trials are needed to fully evaluate the efficacy and tolerability of psychostimulants in this respect. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Methylphenidate treatment for binge-eating disorder in a 12-year-old boy

Önder¹,

Adanır

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…We can say that 8-10 females on 100, aged between 12 and 25 (the age more to risk), suffer of some forms of ED. The mortality is important: it is included between the 5 and 18% for AN and 7% for BN [10][11][12][13][14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies show a modification of the absorption of symptoms in the different syndrome: the symptoms bound to psychological dimension (fear to fatten and desire of thinness) are more frequently verified, while symptoms that interest the somatic sphere are in progressive reduction (loss of weight and amenorrhoea). The survey of a population less grave medical point of view could be the indication of an improvement of the potentiality of a precocious diagnosis [10][11][12][13][14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

“…The quantitative evaluation (entity of loss of weight, frequency of bingeing and purgative behaviours) avails it self of the determination presence/absence of behaviours and their influence on the clinical parameters (BMI, hemato-chemical value, ext); the quantitative evaluation, instead, is related to polarization of thought on the ED: of will be determinate the extension and the possibility to modify this during of clinical colloquy [10][11][12][13][14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

“…The diffusion of "dieting" to internal of all occidental population could induce to increase the tendency to assume restrictive alimentary styles and to put on outward appearance and identity. This explanation could induce arrange the ED like placed to the external "pathological" of a continuum of behaviours that starts in the " physiological" social or professional worry for the weight [10][11][12][13][14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Food behavior as risk factor for developing eating disorders

Milano¹,

Capasso²

2017

Integr Food Nutr Metab

Self Cite

View full text Add to dashboard Cite

Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder

et al. 2015

View full text Add to dashboard Cite

IMPORTANCE Binge-eating disorder (BED), a public health problem associated with psychopathological symptoms and obesity and possibly with metabolic syndrome, lacks approved pharmacotherapies.OBJECTIVE To examine the efficacy and safety of lisdexamfetamine dimesylate, a dextroamphetamine prodrug, to treat moderate to severe BED. DESIGN, SETTING, AND PARTICIPANTSWe performed a randomized, double-blind, parallel-group, forced dose titration, placebo-controlled clinical trial at 30 sites from May 10, 2011, through January 30, 2012. Safety and intention-to-treat analyses included 259 and 255 adults with BED, respectively.INTERVENTIONS Lisdexamfetamine dimesylate at dosages of 30, 50, or 70 mg/d or placebo were provided to study participants (1:1:1:1). Dosages were titrated across 3 weeks and maintained for 8 weeks. We followed up participants for a mean (SD) of 7 (2) days after the last dose. MAIN OUTCOMES AND MEASURESWe assessed the change in binge-eating (BE) behaviors measured as days per week (baseline to week 11) with a mixed-effects model using transformed log (BE days per week) + 1. Secondary measures included BE cessation for 4 weeks. Safety assessments included treatment-emergent adverse events, vital signs, and change in weight. RESULTS At week 11, log-transformed BE days per week decreased with the 50-mg/d (least squares [LS] mean [SE] change, −1.49 [0.066]; P = .008) and 70-mg/d (LS mean [SE] change, −1.57 [0.067]; P < .001) treatment groups but not the 30-mg/d treatment group (LS mean [SE]change, −1.24 [0.067]; P = .88) compared with the placebo group. Nontransformed mean (SD) days per week decreased for placebo and the 30-, 50-, and 70-mg/d treatment groups by −3.3 (2.04), −3.5 (1.95), −4.1 (1.52), and −4.1 (1.57), respectively. The percentage of participants achieving 4-week BE cessation was lower with the placebo group (21.3%) compared with the 50-mg/d (42.2% [P = .01]) and 70-mg/d (50.0% [P < .001]) treatment groups. The incidence of any treatment-emergent adverse events was 58.7% for the placebo group and 84.7% for the combined treatment group. In the treatment groups, 1.5% of participants had serious treatment-emergent adverse effects. Events with a frequency of at least 5% and changes in heart rate were generally consistent with the known safety profile. The mean (SD) change in body weight was −0.1 (3.09), −3.1 (3.64), −4.9 (4.43), −4.9 (3.93), and −4.3 (4.09) kg for the placebo group, the 30-, 50-, and 70-mg/d treatment groups, and the combined treatment groups, respectively (P < .001 for each dose vs placebo group comparison in post hoc analysis). CONCLUSIONS AND RELEVANCEThe 50-and 70-mg/d treatment groups demonstrated efficacy compared with the placebo group in decreased BE days, BE cessation, and global improvement. The safety profile was generally consistent with previous findings in adults with attentiondeficit/hyperactivity disorder. Further investigation of lisdexamfetamine in BED is ongoing. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01291173

show abstract

Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders

Cited by 24 publications

References 0 publications

Methylphenidate treatment for binge-eating disorder in a 12-year-old boy

Methylphenidate treatment for binge-eating disorder in a 12-year-old boy

Food behavior as risk factor for developing eating disorders

Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder

Contact Info

Product

Resources

About